The Danish firm has initiated a Phase I/IIa trial on a long-acting corticotropin-releasing hormone receptor 2 agonist which shows pipeline-in-a-product potential.
The Danish firm has initiated a Phase I/IIa trial on a long-acting corticotropin-releasing hormone receptor 2 agonist which shows pipeline-in-a-product potential.